A hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of the hydrate) for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
Stars
This entity has been manually annotated by the ChEBI Team.
A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
rolapitant hydrochloride (anhydrous)
(CHEBI:90912)
has part
rolapitant(1+)
(CHEBI:90913)
rolapitant hydrochloride (anhydrous)
(CHEBI:90912)
has role
antiemetic
(CHEBI:50919)
rolapitant hydrochloride (anhydrous)
(CHEBI:90912)
has role
neurokinin-1 receptor antagonist
(CHEBI:55350)
rolapitant hydrochloride (anhydrous)
(CHEBI:90912)
is a
hydrochloride
(CHEBI:36807)
Incoming
rolapitant hydrochloride hydrate
(CHEBI:90911)
has part
rolapitant hydrochloride (anhydrous)
(CHEBI:90912)